Evolution of Early SARS-CoV-2 and Cross-Coronavirus Immunity

• DOI: 10.1128/msphere.00622-20
• Publication Date: 2020-09-01T14:33:07Z
• Authors: Carolin Loos; Caroline Atyeo; Stephanie Fischinger; John Burke; Matthew D. Slein; Hendrik Streeck; Douglas Lauffenbu...; Edward T. Ryan; Richelle C. Charles; Galit Alter
• Keywords: 0301 basic medicine; cross-reactivity; Pneumonia, Viral; Medizin; Cross Reactions; Antibodies, Viral; Immunity, Heterologous; Microbiology; Betacoronavirus; 03 medical and health sciences; COVID-19 Testing; Humans; Molecular Biology; Pandemics; Clinical Laboratory Techniques; SARS-CoV-2; COVID-19; antibody response; QR1-502; Immunity, Humoral; 3. Good health; Coronavirus Infections; Fc-receptor binding; Biomarkers; Research Article

A critical step to ending the spread of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the ability to detect, diagnose, and understand why some individuals develop mild and others develop severe disease. For example, defining the early evolutionary patterns of humoral immunity to SARS-CoV-2, and whether prevalent coronaviruses or other common infections influence the evolution of immunity, remains poorly understood but could inform diagnostic and vaccine development. Here, we deeply profiled the evolution of SARS-CoV-2 immunity, and how it is influenced by other coinfections. Our data suggest an early and rapid rise in functional humoral immunity in the first 2 weeks of infection across antigen-specific targets, which is negligibly influenced by cross-reactivity to additional common coronaviruses or common respiratory infections. These data suggest that preexisting receptor binding domain-specific immunity does not influence or bias the evolution of immunity to SARS-CoV-2 and should have negligible influence on shaping diagnostic or vaccine-induced immunity.